Gene expression profiling as a prognostic tool in multiple myeloma

Abstract

Multiple myeloma (MM) is an aggressive plasma cell malignancy with high degrees of variability in outcome, some patients experience long remissions, whilst others survive less than two years from diagnosis. Therapy refractoriness and relapse remain challenges in MM management, and there is a need for improved prognostication and targeted therapies to improve overall survival (OS). The past decade has seen a surge in gene expression profiling (GEP) studies which have elucidated the molecular landscape of MM and led to the identification of novel gene signatures that predict OS and outperform current clinical predictors. In this review, we discuss the limitations of current prognostic tools and the emerging role of GEP in diagnostics and in the development of personalised medicine approaches to combat drug resistance.

Keywords

Multiple myeloma / gene expression profiling / prognostication / risk stratification / risk-adapted therapies / SKY92 / drug resistance

References

[1] Rajkumar SV.Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.Am J Hematol2020;95:548-67

[2] Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells.Cancer Res2018;78:2449-56

[3] Turesson I,Blimark CH,Velez R.Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival.Eur J Haematol2018:237-44 PMCID:PMC6195866

[4] Plackett B.Will the reclassification of multiple myeloma change how people are treated?.Nature2020;587:S56-7

[5] Robiou du Pont S,Fontan C.Genomics of multiple myeloma.J Clin Oncol2017;35:963-7

[6] Broyl A,Lokhorst H.Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.Blood2010;116:2543-53

[7] Szalat R,Munshi NC.Gene expression profiles in myeloma: ready for the real world?.Clin Cancer Res2016;22:5434-42 PMCID:PMC5546147

[8] Chng WJ,Kumar S.Gene signature combinations improve prognostic stratification of multiple myeloma patients.Leukemia2016;30:1071-8

[9] Chng WJ,Chim CS.International Myeloma Working GroupIMWG consensus on risk stratification in multiple myeloma.Leukemia2014;28:269-77

[10] Abdallah N,Greipp P.Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response.Blood Cancer J2020;10:82 PMCID:PMC7419564

[11] Liu Y,Yoo S.A network analysis of multiple myeloma related gene signatures.Cancers (Basel)2019;11:1452 PMCID:PMC6827160

[12] Rajan AM.Interpretation of cytogenetic results in multiple myeloma for clinical practice.Blood Cancer J2015;5:e365 PMCID:PMC4635200

[13] Sawyer JR.The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.Cancer Genet2011;204:3-12

[14] Fonseca R,Drach J.International Myeloma Working GroupInternational Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Leukemia2009;23:2210-21 PMCID:PMC2964268

[15] Greipp PR,Durie BG.International staging system for multiple myeloma.J Clin Oncol2005;23:3412-20

[16] Palumbo A,Oliva S.Revised international staging system for multiple myeloma: a report from International Myeloma Working Group.J Clin Oncol2015;33:2863-9 PMCID:PMC4846284

[17] Shaughnessy JD.Molecular indicators of high-risk disease.Blood2008;112:sci-6

[18] Chng WJ,Bergsagel PL.Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.Leukemia2008;22:459-61

[19] Shaughnessy JD Jr,Usmani S.Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.Blood2011;118:3512-24 PMCID:PMC3186329

[20] Decaux O,Magrangeas F.Intergroupe Francophone du MyélomePrediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.J Clin Oncol2008;26:4798-805

[21] Mulligan G,Bryant B.Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.Blood2007;109:3177-88

[22] Dickens NJ,Leone PE.Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.Clin Cancer Res2010;16:1856-64 PMCID:PMC2841345

[23] Kuiper R,de Knegt Y.A gene expression signature for high-risk multiple myeloma.Leukemia2012;26:2406-13

[24] Zamani-Ahmadmahmudi M,Soltaninezhad F.Development of an RNA sequencing-based prognostic gene signature in multiple myeloma.Br J Haematol2021;192:310-21

[25] Kuiper R,van Vliet MH.Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.Blood2015;126:1996-2004 PMCID:PMC4616233

[26] Biran N,Lentzsch S.SKY92 impacts treatment plan in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial.SSRN Journal

[27] Kuiper R,van Duin M.Gene expression classifier EMC92/SKY92 and revised ISS robustly identify high-risk multiple myeloma in elderly patients of the HOVON-87/NMSG-18 study.Haematologica2017;102:269-70

[28] Kuiper R,van Duin M.Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial.Blood Adv2020;4:6298-309 PMCID:PMC7756986

[29] Marioni JC,Mane SM,Gilad Y.RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays.Genome Res2008;18:1509-17 PMCID:PMC2527709

[30] Settino M,Scionti F.MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers. In: Krzhizhanovskaya VV, Závodszky G, Lees MH, Dongarra JJ, Sloot PMA, Brissos S, Teixeira J, editors. Computational Science - ICCS 2020. Cham: Springer International Publishing; 2020. p. 564-71.

[31] Van Vliet MH,Dumee B.Single sample application of the EMC92/SKY92 signature using the Mmprofiler.Blood2014;124:2026

[32] van Beers EH,Bosman L.Analytical validation of SKY92 for the identification of high-risk multiple myeloma.J Mol Diagn2021;23:120-9

[33] Nadeem O,Anderson KC.Immunotherapeutic and targeted approaches in multiple myeloma.Immunotargets Ther2020;9:201-15 PMCID:PMC7569026

[34] Thorsteinsdottir S,Landgren O.Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.Haematologica2018;103:e412-5 PMCID:PMC6119139

[35] Niewerth D,Assaraf YG,Kaspers GJ.Molecular basis of resistance to proteasome inhibitors in hematological malignancies.Drug Resist Updat2015;18:18-35

[36] Cheung WC.Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells.Leukemia2002;16:1182-8

[37] Harding T,Kumar S.The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.Leukemia2019;33:863-83

[38] Robak P,Szemraj J.Drug resistance in multiple myeloma.Cancer Treat Rev2018;70:199-208

[39] Kumar S,Kaufman JL.Venetoclax monotherapy for relapsed/refractory multiple myeloma: safety and efficacy results from a phase I study.Blood2016;128:488

[40] Punnoose EA,Peale F.Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 Selective antagonist venetoclax in multiple myeloma models.Mol Cancer Ther2016;15:1132-44

[41] Mitra AK,Mukherjee UK.A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.Blood Cancer J2017;7:e581 PMCID:PMC5520403

[42] de Boussac H,Jourdan M.Kinome expression profiling to target new therapeutic avenues in multiple myeloma.Haematologica2020;105:784-95 PMCID:PMC7049359

[43] Herviou L,Boireau S.PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.Clin Epigenetics2018;10:121 PMCID:PMC6171329

[44] Rasche L,Stephens OW.Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.Nat Commun2017;8:268 PMCID:PMC5559527